49. Minapharm Pharmaceuticals

Sector: Pharmaceuticals
Chairman and CEO: Wafik Bardissi
Market Value: $78 million
Sales: $117 million
Profits: $20 million
Assets: $220 million

Minapharm Pharmaceuticals’ history dates back to the 1950s, when the first privately-owned factory in Egypt, Heliopolis Pharmaceutical Laboratories was established. It stopped its activities in the 1960s and was re-established as Minapharm Pharmaceuticals in 1992. Minapharm employs over 1,400 people. In 2023, it received regulatory approval from the Paul-Ehrlich Institute for a phase 1 multi-center clinical trial in Germany for its Adalimumab biosimilar.